Clinical trials: MAB
Communicable Disease Transmission, Zoonotic Disease
A Bridging Study of the SYN023 on Healthy Adult Subjects
The Phase I bridging clinical trial is to evaluate on the safety, pharmacokinetics (PK), pharmacodynamics (PD) and ADA of a single intramuscular injection of recombinant anti-rabies human monoclonal antibody injection (SYN023)…
- Conditions
- Communicable Disease Transmission, Zoonotic Disease, Rabies Human, Vaccine Reaction
- Trial name
- NCT04495569
- Testing
- recombinant anti-rabies human monoclonal antibody injection (SYN023), Rabies Vaccine
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
Non-small Cell Lung Cancer
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after…
- Trial name
- NCT06382129
- Testing
- BL-B01D1, Docetaxel
- Where
- China
- Volunteers
- 698 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Relapsed/Refractory, Multiple Myeloma
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
The purpose of this study is to assess the safety and tolerability, maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-079 monotherapy and when combined with a backbone regimen of pomalidomide and dexamethasone…
- Trial name
- NCT03439280
- Testing
- Mezagitamab, Pomalidomide, Dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Malignant Mesothelioma
The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients.
- Trial name
- NCT01655888
- Testing
- Tremelimumab
- Where
- Italy
- Volunteers
- 29 people
- Sponsor
- Azienda Ospedaliera Universitaria Senese
Non-Small Cell Lung Cancer
A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if participants with untreated locally advanced or metastatic non-small cell lung cancer have a better outcome when treated with olaratumab in combination with paclitaxel/carboplatin then…
- Trial name
- NCT00918203
- Testing
- Olaratumab, Paclitaxel, Carboplatin
- Where
- 23 sites in United States, Canada
- Volunteers
- 137 people
- Sponsor
- Eli Lilly and Company
Non-Malignant Neoplasm
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
This phase I/II trial studies the best dose of total body irradiation with astatine-211 BC8-B10 monoclonal antibody for the treatment of patients with nonmalignant diseases undergoing hematopoietic cell transplant.
- Trial name
- NCT04083183
- Testing
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
The goal of this clinical trial is to learn whether a nasal spray medicine called foralumab is safe and easy to tolerate in adults with amyotrophic lateral sclerosis (ALS).
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- Trial name
- BANYAN (NCT07688239)
- Testing
- Foralumab Nasal
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tiziana Life Sciences LTD
Lymphoma, T-Cell, Peripheral
Alemtuzumab and CHOP in T-cell Lymphoma
The purpose of this study is to determine efficacy and safety of the monoclonal antibody MabCampath® (alemtuzumab) combined with chemotherapy in the treatment of T-cell lymphoma.
- Trial name
- ACT-1 (NCT00646854)
- Testing
- CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab, CHOP14 chemotherapy (see specification under Arm B) plus G-CSF
- Where
- 59 sites in Austria, Belgium and 9 more
- Volunteers
- 136 people
- Sponsor
- Aarhus University Hospital
Inflammatory Bowel Diseases
First Time in Human Study of Intravenous Interleukin-18 Antibody
GSK1070806 is a humanised monoclonal antibody that blocks a protein present in the body called Interleukin-18. The main purpose of this study is to test GSK1070806 in healthy and obese male subjects with normal immune systems to…
- Trial name
- A18110040 (NCT01035645)
- Testing
- GSK1070806
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Squamous Non Small Cell Lung Cancer
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy vs chemotherapy in subjects with locally advanced or metastatic squamous NSCLC…
- Trial name
- NCT04033354
- Testing
- HLX10, carboplatin and nab paclitaxel
- Where
- 92 sites in United States, China and 5 more
- Volunteers
- 537 people
- Sponsor
- Shanghai Henlius Biotech
Alzheimer's Disease
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
- Trial name
- ExpeditionPRO (NCT02760602)
- Testing
- Solanezumab
- Where
- 193 sites in United States, Canada and 11 more
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Chronic Hepatitis C
Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects
The use of oral aCD3 Monoclonal antibody (MAb) alone in subjects with hepatitis C is justified on the basis of scientific and medical reasons.
- Trial name
- NCT01459419
- Testing
- anti-CD3 monoclonal antibody
- Where
- 2 sites in Austria, Poland
- Volunteers
- 36 people
- Sponsor
- Inspira Medical AB
Colorectal Cancer, Esophageal Cancer
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
RATIONALE: Monoclonal antibodies such as ABX-EGF can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00004879
- Testing
- panitumumab
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and dose regimen of CNTO 888 when administered to patients with solid tumors in combination with 4 standard of care chemotherapy regimens.
- Trial name
- NCT01204996
- Testing
- CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection, CNTO888 + gemcitabine, CNTO888 + Paclitaxel and carboplatin
- Where
- 5 sites in United States, Spain
- Volunteers
- 53 people
- Sponsor
- Centocor, Inc.
Malignant Melanomas
An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas
The goal of this clinical trial is provide new treatment for patients with advanced melanoma who have failed previous immunotherapy.
- Trial name
- NCT05928962
- Testing
- Recombinant Human Adenovirus Type 5 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fujian Cancer Hospital
Recurrent Neuroblastoma, Refractory Neuroblastoma
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
This phase I trial studies the side effects and best dose of lenalidomide when given together with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma that does not respond to treatment or…
- Trial name
- NCT01711554
- Testing
- Dinutuximab, Isotretinoin, Laboratory Biomarker Analysis
- Where
- 15 sites in United States, Canada
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to compare the efficacy and safety of SYS6010 in combination with anti-PD-(L)-1 monoclonal antibody vs. anti-PD-(L)-1 monoclonal antibody as adjuvant therapy for patients with.
- Trial name
- NCT07672223
- Testing
- SYS6010, Enlonstobart, Tislelizumab
- Volunteers
- 570 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Myositis, Myasthenia Gravis
Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis
The traditional treatment of inflammatory myopathies (IM) and generalized myasthenia gravis (MG) is immunosuppressive therapy, usually beginning with corticosteroids.
- Trial name
- FORCE (NCT00774462)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Plaque Psoriasis
Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, positive drug parallel-group controlled clinical study in China to evaluate efficacy, safety, tolerability and immunogenicity of HLX03 and adalimumab (Humira) in subjects with…
- Trial name
- NCT03316781
- Testing
- HLX03, adalimumab
- Where
- China
- Volunteers
- 262 people
- Sponsor
- Shanghai Henlius Biotech
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease
Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses.
- Trial name
- NCT03487263
- Testing
- IC14
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Implicit Bioscience
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.